Skip to content

Quality-of-life Impact of Newly Formed Digitalized Printed Paper Inserted Into Eyeglasses

Assessment of the Quality-of-life Impact of Newly Formed Digitalized Printed Paper Inserted Into Eyeglasses for Unilateral Eye Defect Patient Rehabilitation (Clinical Trial)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05857189
Enrollment
18
Registered
2023-05-12
Start date
2023-01-01
Completion date
2023-05-30
Last updated
2023-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orbital Deformity

Brief summary

A straightforward, user-friendly removable orbital prosthesis is a practical choice for effective rehabilitation in such patients with defective eyes. One of the essential elements for a good recovery is the retention of the prosthesis. The prosthesis can be retained by using a spectacle frame, conformers, adhesives, osseointegrated implants, magnets, or buttons. Only osseointegrated prostheses in the maxillofacial region can use semi-precision attachments.

Detailed description

Aim: Using of eyeglasses with newly formed digitalized printed paper of mirrored photograph of an intact eye for orbital defected patients to restore the esthetic appearance. An evaluation of the quality of life for patients using temporalized eyeglasses with digitalized printed paper of mirrored photographs of a healthy eye.

Interventions

DEVICEDigitalized printed paper

Patients will receive a newly formed digitalized printed paper inserted into eyeglasses

DEVICETraditional drawing image

Patients will receive eyeglasses that hold a traditional drawing image of the eye

OTHERHealthy controls

Patients will include volunteering participants with un defected eye

Sponsors

Hams Hamed Abdelrahman
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Crossover between experimental and traditional groups after 2 weeks of lapse time. both groups will be compared to healthy control

Eligibility

Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients with an orbital defective eye (type I). * Patients age more than 6 years. * Patients with a unilateral enucleated eye. * Skin-grafted orbital defects with a lack of natural retentive means either natural undercuts or retaining implants. * Patients who are not prone to be received any prosthetic rehabilitation either for financial, age, or transportation problems of material that are needed for fabrication of prosthetic eye.

Exclusion criteria

* Patients with the bilateral enucleated eye. * Patients with primary signs of skin inflammation, infection, or untreated local disease * Patients refusing to wear any eyeglasses. * Patients with ocular defects.

Design outcomes

Primary

MeasureTime frameDescription
Change in quality of life scoreThrough study completion, average 6 monthseach person's medical chart. Participants will complete the Arabic version of the World Health Organization Quality of Life Instrument, Short Form (WHOQOL-BREF) before and after intervention. The 26- item WHOQOL-BREF Arabic version consists of two overall items measuring general QOL and health condition and 24 items that are universally adopted for the WHOQOL-BREF in four domains: physical health, psychological health, social relationships, and environment. Each item will be rated on a 5- point Likert scale and the domain scores were transformed on a scale from 0 to 100
Patient behaviour toward using the newly designed eye glassesThrough study completion, average 6 monthsThe 14-item visual function questionnaire (VF-14), is based on 14 vision-dependent activities performed in everyday life, and the difficulty undertaking each activity is rated Scores range from 0 to 100, and higher scores represent better visual functioning and less difficulty to perform daily activities.

Countries

Egypt

Contacts

Primary ContactAhmed k Farag, BDS
ahmedfarrag10@hotmail.com01064557964

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026